查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1608057

自体免疫疾病的 IVD 和 LDT 市场：按技术、按应用划分 - 2025-2030 年全球预测

IVD & LDT For Autoimmune Diseases Market by Technology (Clinical Chemistry, Coagulation, Hematology), Application (Addison's Disease, Alopecia Areata, Ankylosing Spondylitis) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，自体免疫疾病的IVD和LDT市值为172.7亿美元，预计到2024年将达到183亿美元，复合年增长率为5.22%，到2030年将达到246.8亿美元。

自体免疫疾病体外诊断（IVD）和实验室测试（LDT）市场范围包括旨在检测和监测自体免疫疾病的诊断工具和测试。对这些测试的需求可以解决类风湿性关节炎、狼疮、多发性硬化症和自体免疫疾病的流行，这些疾病需要准确、及时的诊断以製定有效的治疗计划，这突显了此类疾病的增加。这些诊断主要应用于医院、诊断实验室和研究机构，使临床医生、研究人员和患者受益。主要成长动力包括分子诊断等诊断技术的进步和个人化医疗的兴起。此外，医疗保健支出的增加、易患自体免疫疾病的老年人口的增加以及对疾病早期发现的意识的提高都进一步推动了市场的成长。次世代定序(NGS) 和就地检验的进步体现了最新的潜在机会，产业参与者可以利用策略联盟和技术创新来提高检测的准确性和可靠性。然而，严格的法规环境、与先进诊断测试相关的高成本以及自体免疫疾病的复杂性等挑战可能会阻碍市场扩张。为了缓解这些挑战，公司应该专注于创新领域，例如开发具有成本效益、快速且准确的诊断工具，发现生物标记以及整合人工智慧进行预测诊断。在技​​术快速进步的推动下，市场持续保持动态竞争，对于参与企业来说，透过持续的研发保持领先地位极为重要。透过专注于未满足的诊断需求，特别是代表性不足的自体免疫疾病，并提高全球诊断的可及性，公司可以实现永续成长。监管环境、报销政策和技术整合的整合正在塑造市场的性质，凸显出不断变化的市场格局，适合创新克服现有挑战并利用新机会。

主要市场统计
基准年[2023] 172.7亿美元
预计年份 [2024] 183亿美元
预测年份 [2030] 246.8亿美元
复合年增长率（%） 5.22%

市场动态：针对快速发展的自体免疫疾病 IVD 和 LDT 市场揭示的关键市场见解

供需的动态交互作用正在改变自体免疫疾病 IVD 和 LDT 市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 各国自体免疫疾病的增加
    • 对自体免疫疾病诊断测试的认识不断增强
    • 医疗基础设施的改善和医疗费用的增加
  • 市场限制因素
    • 对神经精神疾病以外的健康问题的担忧
  • 市场机会
    • 体外诊断药物领域的技术进展
    • 加强体外诊断 (IVD)检测套组开发的合作
  • 市场挑战
    • 关于体外诊断药物和LDT的严格规定

波特五力：驾驭自体自体免疫疾病 IVD 与 LDT 市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解自体免疫疾病 IVD 和 LDT 市场的外部影响

外部宏观环境因素在影响自体免疫疾病 IVD 和 LDT 市场表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解自体免疫疾病 IVD 和 LDT 市场的竞争格局

对自体免疫疾病市场 IVD 和 LDT 的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV自体免疫疾病 IVD 和 LDT 市场中的定位矩阵供应商绩效评估

FPNV定位矩阵是评估自体免疫疾病IVD和LDT市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製自体免疫疾病 IVD 和 LDT 市场的成功之路

自体免疫疾病 IVD 和 LDT 市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 经济体中自体免疫疾病的发生率上升
      • 对自体免疫疾病诊断测试的认识不断增强
      • 医疗基础设施的发展和医疗费用的增加
    • 抑制因素
      • 对非神经精神健康问题的担忧
    • 机会
      • IVD领域的技术进步
      • 加强体外诊断（IVD）检测套组开发合作
    • 任务
      • IVD和LDT严格监管
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章自体免疫疾病的 IVD 和 LDT 市场：依技术分类

  • 临床化学
  • 凝固
  • 血液学
  • 免疫检测
  • 微生物学
  • 分子诊断

第七章自体免疫疾病IVD和LDT市场：依应用分类

  • 爱迪生氏症
  • 脱髮症
  • 僵直性脊椎炎
  • 抗磷脂抗体症候群
  • 克隆氏症
  • 1型糖尿病
  • 多发性硬化症
  • 发作性睡病
  • 干癣
  • 类风湿性关节炎
  • 全身性红斑性狼疮
  • 系统性硬皮症
  • 溃疡性大肠炎
  • 葡萄膜炎

第八章美洲自体免疫疾病IVD和LDT市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章 亚太地区自体免疫疾病IVD和LDT市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲自体免疫疾病IVD和LDT市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Adaptive Biotechnologies Corporation
  • Agilent Technologies Inc.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux, Inc.
  • Corgenix, Inc.
  • Creative Biolabs Inc.
  • Diasorin SPA
  • in.vent Diagnostica GmbH
  • Johnson & Johnson Services, Inc.
  • Microbix Biosystems Inc.
  • PerkinElmer, Inc.
  • Roche Diagnostics Corporation
  • SQI Diagnostics Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-ED54C46E8807

The IVD & LDT For Autoimmune Diseases Market was valued at USD 17.27 billion in 2023, expected to reach USD 18.30 billion in 2024, and is projected to grow at a CAGR of 5.22%, to USD 24.68 billion by 2030.

The market scope for In Vitro Diagnostics (IVD) and Laboratory Developed Tests (LDT) for autoimmune diseases involves diagnostic tools and tests designed to detect and monitor autoimmune conditions. The necessity of these tests is underscored by the increasing prevalence of autoimmune disorders, which demand precise and timely diagnosis for effective treatment plans, addressing disorders like rheumatoid arthritis, lupus, and multiple sclerosis. These diagnostics are applied primarily in hospitals, diagnostic laboratories, and research institutions, serving clinicians, researchers, and patients. A key growth driver includes advancements in diagnostic technologies such as molecular diagnostics and the rise in personalized medicine. Additionally, increasing healthcare expenditure, a growing geriatric population susceptible to autoimmune conditions, and rising awareness of early disease detection further fuel market growth. Latest potential opportunities are apparent in next-generation sequencing (NGS) and point-of-care testing advancements, where industry players can leverage strategic collaborations and technological innovations to enhance test accuracy and reliability. However, challenges such as stringent regulatory environments, high costs associated with advanced diagnostic tests, and the complexity of autoimmune diseases can hinder market expansion. To mitigate these challenges, companies should focus on innovation areas such as developing cost-effective, rapid, and highly accurate diagnostic tools, biomarker discovery, and integrating artificial intelligence for predictive diagnostics. The market remains dynamic and competitive, driven by rapid technological advancements, making it crucial for market participants to stay ahead of trends through continuous research and development. By focusing on unmet diagnostic needs, particularly in under-represented autoimmune disorders, and enhancing the accessibility of diagnostics globally, businesses can achieve sustainable growth. The convergence of regulatory approvals, reimbursement policies, and technological integrations shapes the market's nature, highlighting an evolving landscape ripe for innovations that can navigate existing challenges and capitalize on emerging opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 17.27 billion
Estimated Year [2024] USD 18.30 billion
Forecast Year [2030] USD 24.68 billion
CAGR (%) 5.22%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving IVD & LDT For Autoimmune Diseases Market

The IVD & LDT For Autoimmune Diseases Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of autoimmune disorders in economies
    • Increasing awareness regarding diagnostic tests for autoimmune diseases
    • Rising development of healthcare infrastructure and growing healthcare expenditure
  • Market Restraints
    • Concerns regarding extra-neuropsychiatric health problems
  • Market Opportunities
    • Technological advancements in the field of IVD
    • Rising collaborative growth for the development of in-vitro diagnostic (IVD) test kits
  • Market Challenges
    • Stringent regulations of IVDs & LDTs

Porter's Five Forces: A Strategic Tool for Navigating the IVD & LDT For Autoimmune Diseases Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the IVD & LDT For Autoimmune Diseases Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the IVD & LDT For Autoimmune Diseases Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the IVD & LDT For Autoimmune Diseases Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the IVD & LDT For Autoimmune Diseases Market

A detailed market share analysis in the IVD & LDT For Autoimmune Diseases Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the IVD & LDT For Autoimmune Diseases Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the IVD & LDT For Autoimmune Diseases Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the IVD & LDT For Autoimmune Diseases Market

A strategic analysis of the IVD & LDT For Autoimmune Diseases Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the IVD & LDT For Autoimmune Diseases Market, highlighting leading vendors and their innovative profiles. These include Adaptive Biotechnologies Corporation, Agilent Technologies Inc., Bio-Rad Laboratories, Inc., bioMerieux, Inc., Corgenix, Inc., Creative Biolabs Inc., Diasorin S.P.A., in.vent Diagnostica GmbH, Johnson & Johnson Services, Inc., Microbix Biosystems Inc., PerkinElmer, Inc., Roche Diagnostics Corporation, SQI Diagnostics Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the IVD & LDT For Autoimmune Diseases Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Clinical Chemistry, Coagulation, Hematology, Immunoassays, Microbiology, and Molecular Diagnostics.
  • Based on Application, market is studied across Addison's Disease, Alopecia Areata, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Crohn's Disease, Diabetes Type 1, Multiple Sclerosis, Narcolepsy, Psoriasis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Ulcerative Colitis, and Uveitis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of autoimmune disorders in economies
      • 5.1.1.2. Increasing awareness regarding diagnostic tests for autoimmune diseases
      • 5.1.1.3. Rising development of healthcare infrastructure and growing healthcare expenditure
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns regarding extra-neuropsychiatric health problems
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in the field of IVD
      • 5.1.3.2. Rising collaborative growth for the development of in-vitro diagnostic (IVD) test kits
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations of IVDs & LDTs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. IVD & LDT For Autoimmune Diseases Market, by Technology

  • 6.1. Introduction
  • 6.2. Clinical Chemistry
  • 6.3. Coagulation
  • 6.4. Hematology
  • 6.5. Immunoassays
  • 6.6. Microbiology
  • 6.7. Molecular Diagnostics

7. IVD & LDT For Autoimmune Diseases Market, by Application

  • 7.1. Introduction
  • 7.2. Addison's Disease
  • 7.3. Alopecia Areata
  • 7.4. Ankylosing Spondylitis
  • 7.5. Antiphospholipid Antibody Syndrome
  • 7.6. Crohn's Disease
  • 7.7. Diabetes Type 1
  • 7.8. Multiple Sclerosis
  • 7.9. Narcolepsy
  • 7.10. Psoriasis
  • 7.11. Rheumatoid Arthritis
  • 7.12. Systemic Lupus Erythematosus
  • 7.13. Systemic Sclerosis
  • 7.14. Ulcerative Colitis
  • 7.15. Uveitis

8. Americas IVD & LDT For Autoimmune Diseases Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific IVD & LDT For Autoimmune Diseases Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa IVD & LDT For Autoimmune Diseases Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adaptive Biotechnologies Corporation
  • 2. Agilent Technologies Inc.
  • 3. Bio-Rad Laboratories, Inc.
  • 4. bioMerieux, Inc.
  • 5. Corgenix, Inc.
  • 6. Creative Biolabs Inc.
  • 7. Diasorin S.P.A.
  • 8. in.vent Diagnostica GmbH
  • 9. Johnson & Johnson Services, Inc.
  • 10. Microbix Biosystems Inc.
  • 11. PerkinElmer, Inc.
  • 12. Roche Diagnostics Corporation
  • 13. SQI Diagnostics Inc.
  • 14. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET RESEARCH PROCESS
  • FIGURE 2. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET DYNAMICS
  • TABLE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COAGULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ADDISON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ALOPECIA AREATA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTIPHOSPHOLIPID ANTIBODY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIABETES TYPE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY NARCOLEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY UVEITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. SINGAPORE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. SOUTH KOREA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. SOUTH KOREA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. TAIWAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. TAIWAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. THAILAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. THAILAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. VIETNAM IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. VIETNAM IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 73. DENMARK IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. DENMARK IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. EGYPT IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. EGYPT IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. FINLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. FINLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. FRANCE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. FRANCE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. GERMANY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. GERMANY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. ISRAEL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. ISRAEL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. ITALY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. ITALY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. NETHERLANDS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. NETHERLANDS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. NIGERIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. NIGERIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. NORWAY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. NORWAY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. POLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. POLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. QATAR IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. QATAR IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. RUSSIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. RUSSIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SAUDI ARABIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. SAUDI ARABIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. SPAIN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. SPAIN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. SWEDEN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. SWEDEN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. SWITZERLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. SWITZERLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. TURKEY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. TURKEY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED ARAB EMIRATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED ARAB EMIRATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED KINGDOM IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED KINGDOM IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 116. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023